APR 2 7 2005

510(k) Summary of Safety and Effectiveness

K041554

This 510(k) Summary of Safety and Effectiveness for the AesThera AIP ™ Intense Pulsed Light System is submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990 and follows the Office of Device Evaluation (ODE) guidance concerning the organization and content of a 510(k) summary.

Applicant:

AesThera Corporation

6111 Southfront Road

Suite E

Livermore, CA 94550

Bob Anderson

Chief Financial Officer

Contact Person:

C. Robert Payne, Jr., P.E.

Regulatory Affairs Consultant

CRP Enterprises P.O. Box 2608

Morgan Hill, CA 95038 Telephone: (408) 782-3024

Fax: (408) 779-5284

e-mail: myrvhome@ix.netcom.com

Preparation Date:

6 June 2004

Device Trade Name:

AIP[™] Intense Pulsed Light System

Common Name:

Pulsed Flash Lamp

Classification Name:

Surgical instrument for use in general and

plastic surgery and in dermatology

(21 CFR 878-4810)

Product Code:

GEX

Predicate Devices:

 SkinStation[™], SPR[™], ClearTouch[™], SpaTouch Pro (XtremeClear[™]), SpaTouch[™] (Radiancy (Israel) Ltd.) (K032205, K033181, K030897, K020856, K992482)

• StarLux[™], MediLux[™], EsteLux[™] (Palomar Medical Technologies, Inc.) (K033549, K020941, K020453, K010618, K003886)

Device Description:

The AesThera AIP Intense Pulsed Light System is a 400–1200 nm intense pulsed light delivery system, powered by Photo-PneumaticTM technology. It is a portable tabletop system with a hand piece connected by an umbilical to the main console. The hand piece incorporates an intelligent tip that is replaced with every patient treatment. A "sealed" intelligent tip is used to transmit light to the patient's skin. Light is emitted only through the tip and is always sealed with the patient's surrounding tissue during intense pulsed light emission. All emitted light is contained within the tip during treatment. The hand piece of the AIP Intense Pulsed Light System is uniquely designed to promote increased ergonomics with all user interface and controls located on the hand piece.


Intended Use of the <u>Device</u>:

The AIP Intense Pulsed Light System is an intense pulsed light device intended for the following: the treatment of benign vascular and pigmented lesions, and permanent hair reduction.

The AIP Intense Pulsed Light System is intended for use on all skin types (Fitzpatrick skin types I-VI).

Substantial Equivalence to Predicate Devices:

The AIP Intense Pulsed Light System, which is intended for the following; the treatment of benign vascular and pigmented lesions, and permanent hair reduction, is substantially equivalent in design and materials to the listed predicate devices.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 2 7 2005

AesThera Corporation C/o C. Robert Payne, Jr., P.E. RA/ QA Consultant CRP Enterprises P.O. Box 2608 Morgan Hill, California 95038

Re: K041554

Trade/Device Name: AIPTM Intense Pulsed Light System

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and in

dermatology

Regulatory Class: II Product Code: GEX Dated: March 16, 2005 Received: March 21, 2005

Dear Mr. Payne:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number:	New submission K041254
Device Name:	AIP ™ Intense Pulsed Light System
Indications for Use	
The AIP Intense Pulsed Light System is an intense pulsed light device intended for the following: the treatment of benign vascular and pigmented lesions, and permanent hair reduction.	
The AIP Intense Pulsed Light System is intended for use on all skin types (Fitzpatrick skin types I-VI).	
Prescription U	Jse X Over-the-Counter Use (per 21 CFR 878-4810)
(Please do not write below this line – Continue on another page if needed)	
Concurrence of CDRH, Office of Device Evaluation (ODE)	
iden of Commit Portanciivo	
Former 4041554	
	D-2